Newsroom
Follow Our Journey On Social Media
Latest News
BrYet US, Inc. Receives Approval to Initiate in Australia a First-in-Human Phase 1/2 Trial of ML-016 in Advanced Cancers with Lung and/or Liver Involvement
HOUSTON and SUNSHINE COAST, Queensland (October 6, 2025) — BrYet US, Inc. (“BrYet”), a biotechnology innovator developing a drug with the potential to be a first-in-class medicine for metastatic disease, today announced that it has received an Australian Human Research Ethics Committee (HREC) approval for its first-in-human clinical study of ML-016....
Results Published In Leading Scientific Journals
Nature Biotechnology
An injectible nanoparticle generator enhances delivery of cancer therapeutics
Science Advances
Sequential deconstruction of composite drug transport in metastatic breast cancer
Nature Reviews Cancer
Approaches from the physical sciences can contribute to the rate at which powerful new diagnostic tools and therapies can be discovered.
Cancer Research
Targeting autocrine CCL5–CCR5 axis reprograms immunosuppressive myeloid cells and reinvigorates antitumor immunity
Clinical Cancer Research
Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery
Cell Reports
Porous silicon microparticle potentiates anti-tumor immunity by enhancing cross-presentation and inducing type I interferon response
Controlled Release
Co-delivery of tumor antigen and dual toll-like receptor ligands into dendritic cell by silicon microparticle enables efficient immunotherapy against melanoma
Nature Biotechnology
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Advanced Science
Synergistic activation of antitumor immunity by a particulate therapeutic vaccine